Introduction
Alzheimer's disease (AD) is the most common form of dementia, defined clinically as a progressive loss of declarative memory, leading to complete social dependence and eventually death. It is characterised by cerebral extracellular amyloid plaques and intracellular neurofibrillar tangles. [1] The molecular mechanisms of AD pathogenesis are still not fully understood [2, 3] because of its intrinsic complexity. No effective treatment has been developed. Nevertheless, it has been shown that polymerisation of the b-amyloid peptide (Ab) into amyloid fibrils and other morphologies, including plaques and oligomeric species, constitutes a major hallmark of AD. [4] The development of Ab inhibitors has thus received much attention, with peptides [5] [6] [7] and small organic molecules [8] [9] [10] now established as the two main classes of amyloid inhibitor. Ab production, aggregation and accumulation within the brain is summarised in Figure 1 .
Since the discovery that Ab peptides are found within the mitochondria of AD brains, [11] several attempts have been made to comprehend the mechanisms underpinning Abinduced mitochondrial dysfunction, [12] [13] [14] [15] [16] [17] [18] [19] [20] and to identify recep-A major hallmark of Alzheimer's disease (AD) is the formation of toxic aggregates of the b-amyloid peptide (Ab). Given that Ab peptides are known to localise within mitochondria and interact with 17b-HSD10, a mitochondrial protein expressed at high levels in AD brains, we investigated the inhibitory potential of 17b-HSD10 against Ab aggregation under a range of physiological conditions. Fluorescence self-quenching (FSQ) of Ab labelled with HiLyte Fluor 555 was used to evaluate the inhibitory effect under conditions established to grow distinct Ab morphologies. 17b-HSD10 preferentially inhibits the formation of globular and fibrillar-like structures but has no effect on the growth of amorphous plaque-like aggregates at endosomal pH 6. This work provides insights into the dependence of the Ab-17b-HSD10 interaction with the morphology of Ab aggregates and how this impacts enzymatic function. Figure 1 . Production, aggregation and accumulation of Ab peptides within the brain is associated with neural dysfunction. Ab peptides are formed in the cell membrane by cleavage of the amyloid precursor protein (APP) by bsecretase cleaving enzymes (BACEs). Soluble Ab oligomers interact with cellsurface membranes and receptors, as well as intracellular components to lead to neuronal dysfunction. In particular, Ab interaction with 17b-HSD10 in the mitochondria can lead to the inhibition of 17b-HSD10 activity, in turn leading to mitochondrial dysfunction. Ab can self-assemble into pathogenic fibrils, plaques and other higher-order structures, thereby displacing vital cellular components and leading to their malfunction.
tors that might be involved in this process. [21] The interaction between mitochondrial proteins and aggregated Ab peptides has been suggested as a pathogenic mechanism contributing to Ab neurotoxicity in AD. [17] [18] [19] [20] [21] [22] For instance, 17b-hydroxysteroid dehydrogenase type 10 (17b-HSD10; also known as amyloid-binding alcohol dehydrogenase (ABAD)) [21, [23] [24] [25] [26] is one such mitochondrial Ab-interacting protein. [6, 27] 17b-HSD10, a 27 kDa multifunctional enzyme expressed in all cell types, is thought to play a central role in the b-oxidation of fatty acids, [24, 28] isoleucine degradation, the catalysis and oxidation of alcohols and the reduction of aldehydes and ketones. [22] In transgenic mouse models for AD and in human AD sufferers, 17b-HSD10 has been shown to have increased expression; it has gained considerable attention as a result of its ability to bind Ab and to suppress Ab-induced apoptosis and free-radical generation in neurons. [11] 17b-HSD10 interacts with Ab(1-40), Ab(1-42) and Ab (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) (18) (19) (20) in the nanomolar range (K d 40-80 nm), [11] which reflects the low expected cellular concentration of Ab peptide in the early stages of AD. Mutagenesis and inhibition studies have suggested that the L D loop of 17b-HSD10 (residues C91-D119) plays a critical role in Ab binding. [11] However, the lack of electron density for Ab and the L D loop of 17b-HSD10 in the crystal structure (PDB ID: 1SO8) of the complex precludes detailed characterisation of the binding interface. A recent NMR study suggested that the 17b-HSD10-Ab interaction takes place mostly by contacts between Ab residues 17-20 (LVFF) and hydrophobic residues in L D . [29] Importantly, saturation transfer difference (STD) NMR experiments suggested that the binding of Ab and nicotinamide adenine dinucleotide (NAD) to 17b-HSD10 is mutually exclusive, thus providing an explanation for how Ab-binding alters the activity of 17b-HSD10. [29] The interaction between 17b-HSD10 and Ab in vivo has been demonstrated within mitochondria by using co-localisation and co-immunoprecipitation techniques, [11] but many aspects of this interaction remain poorly understood.
Here, we employed a fluorescence self-quenching (FSQ) approach to investigate the interaction between 17b-HSD10 and amyloid aggregates. FSQ was based on the site-specific positioning of a fluorescent dye HiLyte Fluor 555 ( Figure S1 in the Supporting Information) at the N terminus of Ab. In FSQ, the fluorescence of the dye is highest for non-aggregated Ab(1-42) but becomes progressively quenched as monomers aggregate, thereby resulting in a combination of partially quenched and non-emissive fluorophores (Figure 2) , thus decreasing the emission as aggregation progresses. The advantages of FSQ over extrinsic dyes such as thioflavin-T (ThT) to Ab aggregates have been discussed. [29, [33] [34] [35] There are many reasons for the present work. Firstly, we want to assess the applicability of FSQ for investigating the interaction between amyloid and 17b-HSD10, as has been previously shown for the interaction between Ab and Hsp20 (heat shock protein, 20 kDa). [33] Secondly, despite in vivo evidence for an association of 17b-HSD10 and Ab, it is not known whether 17b-HSD10 inhibits all amyloid morphologies equally or whether it has selectivity for some types of aggregate. In addition to inhibiting amyloid aggregation, it has been shown that 17b-HSD10 when in complex with Ab becomes dysfunctional, and that its enzymatic inactivation leads to an increase in mitochondrial stress and ultimately loss of neuron viability. [36] However, no in vitro data has been reported to confirm this, and it is unclear how the two consequences of the interaction between 17b-HSD10 and Ab (inhibition of aggregation and enzymatic inactivation of 17b-HSD10) are related.
Our results with FSQ demonstrate that 17b-HSD10 specifically inhibits the formation of NaCl-induced fibrils and globular aggregates, but that this has no effect on the formation of plaque-like structures grown at endosomal pH. Furthermore, by monitoring the conversion of NADH into NAD + through an absorbance assay, we investigated the impact of these morphologies on the enzymatic function of 17b-HSD10. Although the formation of fibrils and globules was inhibited to similar extents by 17b-HSD10, their influences on 17b-HSD10 function were significantly different, with fibrillar structures showing the highest enzymatic inhibition. Lastly, a comparison between FSQ and the widely used ThT-based assay revealed that the ThT reporter dye exhibits, even in the absence of amyloid, a significant time-dependent fluorescence enhancement under the aggregation conditions used to promote the formation of globular amyloid structures. Thus, our findings highlight the limitations of ThT-based methods to monitor aggregation across different conditions and confirm that the FSQ-based assay is a superior analytical tool to investigate amyloid self-as- 
Results

Monitoring amyloid aggregation and inhibition by FSQ
Aggregation of Ab functionalised at the N terminus with HiLyte Fluor 555 (Ab 555 ) into three morphologies (globules, fibrils and plaques) was studied in real-time by FSQ, with Ab/ 17b-HSD10 molar ratios of 1:1, 2:1 and 1:0 (control). The rationale for choosing these morphologies was twofold. Firstly, they constitute representative examples of the vast array of amyloid morphologies than can be generated as a function of environmental conditions. [43] Secondly, there are well-established aggregation protocols to reproducibly promote the formation of Ab aggregates, and these aggregates have been extensively characterised by structural imaging methods, including atomic-force microscopy (AFM) and electron microscopy (EM). [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] [43] [44] [45] [46] [47] [48] [49] [50] [51] We previously demonstrated by EM that the presence of HiLyte Fluor 555 at the N terminus of the Ab(1-42) does not affect the aggregation kinetics or the morphology of the aggregates.
[34] Indeed, we observed amyloid structures of Ab 555 with diameters of~4 nm (fibrils) and~22 nm (globules), identical to those obtained in the absence of N-terminal functionalisation. [32, 33, 52] At pH 6 and pH 4 we observed the formation of amorphous plaque-like aggregates, as previously reported under similar acidic conditions. [52] The concept of the FSQ-based assay should be summarised before describing our findings from its application to the interaction between Ab and 17b-HSD10. FSQ methods rely on close positioning of the dyes as a result of the tight packing of amyloid chains in the aggregated structures. This induces very efficient quenching, which results in the observed time-dependent decrease in fluorescence emission of HiLyte Fluor 555 [34] as aggregation progresses, as this depends on the proximity and local density of identical dyes in the neighbourhood of a given fluorophore (Figure 2 ). An in-register parallel beta-sheet packing that placed the N-terminal domains next to each other was recently demonstrated by solid-state NMR, [43] and this provided a molecular-level explanation of how the organisation of the amyloid fibrils enables very efficient self-quenching. As suggested in that work, the hydrophobic assembly of two or more of these protofibrils might be possible, and this could also contribute to placing the dyes in close proximity.
17b-HSD10 inhibits the formation of fibril-like structures
The kinetics of amyloid aggregation and the predominant morphologies arising from this process are known to be extremely sensitive to environmental conditions including pH, temperature and ionic strength. [42, 52] For instance, we have previously demonstrated by TEM, FSQ and ThT assays that fibrillar structures constitute the predominant morphology at pH 7.9 and moderate concentrations of NaCl (150 mm). [33] Here, we used similar conditions to determine the impact of 17b-HSD10 on the formation of these amyloid aggregates. In the absence of 17b-HSD10, when a non-aggregated solution of 1 mm Ab 555 was incubated in 50 mm Tris·HCl (pH 7.9) with 150 mm NaCl at 37 8C, we observed a fluorescence decrease of 23.1 AE1.2 % (Figure 3 A) . When 1 mm Ab 555 was induced to aggregate in the presence of 17b-HSD10 under the same conditions, significant inhibition was detected at the two Ab 555 /17b-HSD10 molar ratios: 7.7 AE 0.5 % quenching at 2:1 ( In order to validate and compare our FSQ assay against an established method, we used ThT as a sensor of amyloid fibril aggregation. [38] ThT ( Thus, in agreement with the data obtained by FSQ, the ThT-based assay showed that 17b-HSD10 interacts with Ab(1-42) and efficiently inhibits the formation of amyloid fibrils in a concentrationdependent manner (spectra of Ab 555 at these Ab/17b-HSD10 ratios in Figure S2 ; quenching rates obtained from global fits of the aggregation profiles at these ratios by FSQ and ThT in Table S1 ).
The dependence of inhibitory effect on 17b-HSD10 with the Ab 555 /17b-HSD10 molar ratio agrees well with the observation that 0.5 mm "in vitro aged" Ab(1-42) had no effect on 17b-HSD10 dehydrogenase activity, whereas at tenfold higher concentration Ab(1-42) caused substantial inhibition (~50 %). [23] The inhibitory effect observed here for 17b-HSD10 against fibrillar aggregates is similar to that observed for other proteins with no reported chaperone activity, such as b-lactoglobulin, a-lactalbumin and lysozyme. [58] These proteins have been shown to delay the formation of fibrillar aggregates at 1:1 molar ratio, whereas the enzymes catalase and pyruvate kinase completely suppressed amyloid aggregation at a much lower ratio (protein/Ab, 1:100). [58] Several mechanisms have been proposed to explain the inhibitory effect of these proteins at substoichiometric amounts, including interactions with monomeric peptides in the b-sheet conformation and the formation of complexes with pre-fibrillar oligomers to slow or prevent the growth into fibrils. It is unclear whether the inhibitory effect we observed for 17b-HSD10 towards the formation of fibrillar oligomers in both the FSQ and ThT assays involve similar mechanisms to those when acting on non-chaperone proteins. However, the fact that no interaction between 17b-HSD10 and monomeric Ab was observed by surface-plasmon resonance (SPR) [11] and that no binding was observed in the NMR titration of 17b-HSD10 into amyloid monomers [29] suggests that 17b-HSD10 might act by forming "dead-end" Ab-17b-HSD10 aggregates, as observed for b-lactoglobulin and catalase, as determined by 1 H, 15 N HSQC NMR spectroscopy.
17b-HSD10 inhibits the formation of rapidly growing globular aggregates
The formation of soluble amyloid oligomers and spherical aggregates is known to induce rapid cell degeneration, thus suggesting that soluble Ab aggregates have higher toxicity than plaques and Ab fibrils. [51] The formation of these globular species is known to be accelerated in the presence of lipids and other interfaces (a process that, under certain conditions, can lead to the formation of Ab pores that disrupt the cellular membrane). [48] The addition of small amounts of fluorinated solvents such as 1,1,1,3,3,3-hexafluoropropan-2-ol (HFIP) and 2,2,2-tri-fluoroethanol (TFE) as co-solvents to a solution of monomeric Ab has been demonstrated as a method to induce the formation of amyloid aggregates. [46] For instance, HFIP at 4 % (v/v) induced the formation of globular structures in vitro. [42] HFIP droplets formed at these concentrations in an aqueous solution have been hypothesised to act as a growing interface where amyloid monomers can nucleate and accelerate growth, as observed at the interface of biomimetic membranes, including ganglioside micelles and lipid-rafts. [48] Moreover, it has been proposed that the toxicity of these globular structures is responsible for the cognitive problems associated with the use of polyfluorinated anaesthetic compounds. [55] In order to investigate the interaction and potential inhibitory properties of 17b-HSD10 under these globular-forming conditions, we carried out FSQ experiments with 1.5 % (v/v) HFIP. We previously showed that, at this concentration, HFIP induced Ab aggregation over several minutes, easily followed in real-time by FSQ. [33] [34] In the absence of 17b-HSD10, the addition of 1.5 % (v/v) HFIP to a non-aggregated solution of 1 mm Ab 555 in 50 mm Tris·HCl buffer (pH 7.9) at 4 8C with continuous agitation induced a decrease in fluorescence intensity of 60 AE 4 % over 30 min (Figure 4 A) . When 1 mm Ab 555 was induced to aggregate under the same conditions but with 17b-HSD10 at 2:1 and 1:1 Ab 555 /17b-HSD10, self-quenching was 19 AE 4 % and 13 AE 3 %, respectively (Figure 4 A) . Importantly, no quenching was observed over 30 min when Ab 555 and 17b-HSD10 were incubated at a 1:1 molar ratio in the absence of HFIP ( Figure S3 ), thus confirming that under these conditions, 17b-HSD10 interacts with Ab during HFIP-induced self-assembly.
For comparative purposes, we also explored the use of ThT fluorescent enhancement to monitor the formation of these globular structures as well as its inhibition by 17b-HSD10. Interestingly, injection of < 4 % (v/v) HFIP into 1.5 mm ThT (in 50 mm Tris·HCl, pH 7.9, 4 8C) induced a significant (~fourfold) increase in fluorescence over 5-10 min, even in the absence of amyloid (Figure 4 B) . ThT emission enhancement has been extensively used as a reporter of HFIP-induced aggregation; [41, 45] the emission behaviour of ThT in different restricted media, including b-sheet and non-b-sheet cavities, such as cyclodextrin, polymer films, and micelles, has been discussed. [45] In contrast, no detailed investigation of ThT in mixtures of water and polyfluorinated solvents, which are known to form microdroplets and solvent clusters, [47] has been reported. However, the formation of HFIP micro-droplets acting as adsorption platforms for BSA by TEM analysis has been reported, [42] and micro-heterogeneities in HFIP-water mixtures have been studied in detail by NMR and small-angle neutron scattering (SANS); these revealed a correlation in lengths ranging from 7 to 10 . [54] Interestingly, these lengths match the diameter (8-9 ) of g-cyclodextrin cavities, which are known to promote the characteristic enhancement in ThT emission. [45] From NMR and SANS data it was suggested that these micro-heterogeneities are maximised at HFIP concentrations of 30-35 % (v/v), and that the clusters organise with the trifluoromethyl (CF 3 ) groups pointing inside the core and hydroxy (OH) groups forming hydrogen bonds with the surrounding water molecules. [54] At lower concentrations of HFIP (< 5 % v/v), oligomers were detected by MS, but their size and stoichiometry were unknown. [54] The influence of HFIP on the photophysical properties of ThT in aqueous solution was further investigated by monitoring its absorption spectrum as a function of HFIP concentration. We observed a significant decrease in absorption after addition of 1.5 % and 4 % (v/v) HFIP (Figure S4 ), whereas higher concentrations (~30 %) reversed this behaviour and shifted the absorption maximum ( Figure S4 ). Similar features were found in the absorption (Figure S5 A) and emission spectra (Figure S5 B) when using TFE in place of HFIP, although this was less pronounced. These results suggest that the observed differences in photophysical properties of ThT might arise from an interaction with the droplet-water interface, which alters its molecular-rotor properties, or from local changes in the dielectric constant, which is known to influence ThT emission. [47] This clearly indicates that care should be taken when using it as a reporter of amyloid aggregation in mixtures of water and polyfluorinated solvents.
In view of the uncertainties associated with the use of ThT to monitor HFIP-induced aggregation and to take into account the spherical organisation of the globular aggregates, we employed dynamic light scattering (DLS) as an alternative to FSQ, and compared the results. We wished to determine how these HFIP-induced aggregates are affected by the presence of 17b-HSD10. In the absence of 17b-HSD10, the values for the hydrodynamic radius (R H ) were broadly distributed between 60 and 400 nm (Table S2) . These values are in good agreement with those previously reported by DLS and multi-angle light scattering (200-300 nm) for globule growth at similar HFIP concentrations. [41] Upon incubation with 17b-HSD10, a marked decrease in R H was observed at both 2:1 and 1:1 Ab/17b-HSD10: 44.9-108.0 and 36-150 nm, respectively, correspond to a decrease in mass of close to an order of magnitude (Table S2) . We interpret the decrease in average R H as additional evidence for the inhibitory effect of 17b-HSD10 on globular aggregation.
Taken together, the FSQ and DLS data provide clear evidence of 17b-HSD10 inhibiting the formation of globular aggregates, and suggest that the interaction of 17b-HSD10 with Ab(1-42) must be at a rate that competes with the relatively fast average aggregation rate reported for the globular aggregate (< 2 min À1 ). [34] It has been shown that freshly prepared HFIP-induced globules are highly unstable after dilution and evolve over time into more stable and still soluble fibrillar aggregates. [34, 42] Based on this, we hypothesise that the inhibitory action of 17b-HSD10 towards globular species might involve the interaction and sequestering of Ab material that is in dynamic exchange with the globular structures. Equilibrium between globules and low-molecular-weight Ab structures is strongly supported by the evolution of these globules into more-stable structures over time. Remarkably, the ability of 17b-HSD10 to disrupt the formation of globular aggregates was significantly more pronounced than that reported for chaperone proteins aB-crystallin [57] and Hsp20, [33] which constitute examples of natural defence against protein misfolding. [33] For instance, wild-type Hsp20 did not interfere with the formation of globular aggregates even at an Ab/Hsp20 molar ratio of 1:2 (higher than used here for 17b-HSD10). [33] 17b-HSD10 does not inhibit amorphous plaque-like aggregate formation under acidic conditions Ab peptides are found within the mitochondria of AD brains, [11] and it has been suggested that soluble Ab aggregates (monomeric and oligomeric structures) enter the mitochondria via the translocase of the outer membrane (TOM) machinery. [12] As 17b-HSD10 is a mitochondrial protein, it is unlikely to interact with large plaque-like material usually found to aggregate in lysosomes under slightly acidic conditions (pH 6); however, no direct experimental evidence had been reported to confirm this. Therefore, we decided to take advantage of the robustness of FSQ over a wide pH range to test the potential interaction between 17b-HSD10 and plaque-like aggregates formed at Ab 555 /17b-HSD10 molar ratios similar to those used to investigate the interaction with globules and fibrils. In the control experiment, 1 mm Ab 555 in 2-(N-morpholino)ethanesulfonic acid (MES) buffer (50 mm, pH 6) at 378C induced a decrease in fluorescence of 21.1 AE 0.5 % over 50 min (Figure 5 A) . However, no significant inhibition was detected for Ab 555 /17b-HSD10 molar ratios of 2:1 and 1:1 (FSQ largely unchanged: 21.1 AE 0.9 % and 14.4 AE 0.7 %, respectively; Figure 5 B, C; Ab 555 quenching under these conditions in the presence and absence of 17b-HSD10 is in Table S3 ; spectra at the different molar ratios are in Figure S6) .
Although amyloid staining methods based on extrinsic probes, such as ThT, are known to suffer from a decrease in affinity (< 30-fold) when the pH is decreased from pH 8.5 to 6, [40] 
Amyloid-induced inactivation of 17b-HSD10 enzymatic function
17b-HSD10 was the only human protein found to interact with Ab in a yeast two-hybrid screen, [21] thus suggesting that Ab-induced cytotoxicity occurs mostly by its interaction with 17b-HSD10. [18, 36, 50] The current hypothesis is that HSD10 in complex with Ab becomes dysfunctional and leads to increased mitochondrial stress and ultimately loss of neuron viability. [50] The inhibitory effect of Ab(1-42) on 17b-HSD10 binding to the NADH/NAD + cofactor has already been confirmed by SPR and STD NMR. [29] However, the precise morphological state of Ab(1-42) that inactivates 17b-HDS10 has not been established. Our FSQ data indicate that 17b-HDS10 interacts with fibrillar and globular amyloid structures but not with plaques; therefore, we decided to investigate the enzymatic activity of 17b-HDS10 under fibril-and globule-growing conditions.
Before assessing the influence of amyloid aggregation state on the function of 17b-HSD10, it was important to verify that the enzyme was active in the buffers required to promote these morphologies. For this, we employed an assay that monitors changes in NADH absorbance. During 17b-HSD10 conversion of acetoacetyl coenzyme A, the cofactor NADH is converted into NAD + . Thus, the loss of NADH absorbance (340 nm) is a measure of 17b-HSD10 activity (Figure 6 A) . When incubated at 5 mg mL À1 , 17b-HSD10 showed a specific activity of 4 mmol min À1 mg À1 (Figure 6 B) ; the negative control (no 17b-HSD10 in the reaction mixture) showed minimal background (~0.2 mmol min À1 mg
À1
). Under conditions that promote both oligomeric/ fibril formation (50 mm Tris·HCl (pH 7.9) containing 150 mm NaCl) and globular aggregation (50 mm Tris·HCl (pH 7.9) containing 1.5 % (v/v) HFIP) there was no change in specific activity (Figure 6 B) . Under plaque-growing conditions (50 mm MES, pH 6.0, 37 8C) there was a very slight decrease in activity (< 4 %; Figure 6 B) .
When the absorbance assay was repeated under conditions that induce amyloid aggregation we observed a morphologydependent response. Under fibril-promoting conditions, enzymatic inhibition depended on the Ab(1-42)/17b-HSD10 molar ratio: the enzymatic activity decreased by 3.4 AE 1.9 % at 1:1 and 20.2 AE 1.6 % at 2:1 (Figure 6 C) . For conditions that promote the formation of globular structures, we observed a very moderate decrease in the enzymatic activity (5.4 AE 1.7 %), even at the highest ratio (5:1). These data suggest that different amyloid morphologies exhibit different inhibition of 17b-HSD10, and confirm that, in a rich amyloid environment, Ab(1-42) fibrils have a deleterious effect on 17b-HSD10 activity.
Discussion
A bar plot summarising relative fluorescence self-quenching for the aggregation of 1 mm Ab 555 into globular, fibrils and amorphous plaque-like aggregates in the presence and absence of 17b-HSD10 is shown in Figure 7 A; the results from a ThT-based assay for fibrils and plaques is shown in Figure 7 B. Both methods provide strong evidence for 17b-HSD10 preferentially interacting with certain amyloid morphologies. Specifically, 17b-HSD10 demonstrated inhibitory potential towards globular and fibrillar structures formed at neutral pH, but had no effect on the aggregation of plaque structures formed at pH 6. A degree of preferential interaction of 17b-HSD10 with some amyloid aggregates could be anticipated, as the crystal structure of the 17b-HSD10/Ab(1-42) complex (PDB ID: 1SO8) reveals a large cavity (~70 ), which could easily accommodate fibrillar structures (40-60 ), but not, for instance, plaque-like aggregates. [11] The stoichiometry of the Ab-17b-HSD10 complex has not been determined, but it has been hypothesised that 17b-HSD10 does not interact with Ab(1-42) monomers in SPR and NMR experiments. [11, 29] Therefore, it is unlikely that physical and/or structural differences between the monomeric state of Ab(1-42) at different pH values can account for the observed discrimination between plaque-like structures formed at pH 6 and fibrils and globules formed at neutral pH. Moreover, under conditions identical to those used to generate amorphous plaque-like aggregates, 17b-HSD10 showed enzymatic levels comparable to that at neutral pH (Figure 6 B) , thus confirming that the numerous interactions formed by the substrate with loops L F, L E and L D are retained under slightly acidic conditions. In particular, the L D loop region, which has been shown by mutagenesis studies and NMR analysis to form the interface with Ab, [29] should remain accessible for Ab binding. Because 17b-HSD10 was present in the aggregation mixture from the very early stages in all our assays, we hypothesise that either differences in the structures of the aggregation intermediates or in the kinetics of the aggregation between neutral and slightly acidic conditions might be responsible for the observed differences. This is supported by evidence suggesting that indeed both amyloid morphology and aggregation kinetics at pH 6 are remarkably different to those at neutral pH. [39, 60] Recent in vivo studies have demonstrated that neuronal Ab aggregates faster in lysosomes and without a detectable lag phase; this finding was attributed to the acidic environment bringing the peptide closer to its isoelectric point. [61] By using a combination of fluorescence methods and structural techniques, it was shown that amyloid aggregation at pH 5.8 is characterised by the rapid formation (~10 s) of amorphous aggregates, with sizes ranging from 50 to 500 nm. [40] Importantly, as determined by CD, these aggregates did not contain a-helical or b-structures, and they were unable to seed fibril formation. [40] It was also demonstrated that the aggregates evolve into smaller structures (30-80 nm) after 30 min, in good agreement with the time for aggregation observed in our FSQ and ThT experiments ( Figure 5 ). The time scale of the initial growth phase is within our mixing time, so it is likely that with the time course of our assay, we were monitoring the disappearance of the initially formed aggregates as they slowly evolved into other morphologies. As reported by Gorman and co-workers, [39] these slow-forming morphologies also display very little (if any) b-structure. However, a lack of b-sheet structure at acidic pH cannot alone account for the observed lack of aggregation inhibition, as it has been shown that 17b-HSD10 does not bind Ab (25) (26) (27) (28) (29) (30) (31) (32) (33) (34) (35) , which has been shown to exhibit b-sheet conformation in CD and NMR studies. [63] In contrast, the conformation of residues 17-20 of Ab (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) (18) (19) (20) , which constitute the binding interface with 17b-HSD10, [11] is known to exhibit a random-coil/a-helix/b-sheet equilibrium that is highly dependent on pH. [61, 63, 64] At pH 7-8, it has been demonstrated that residues 10-28 (containing the putative 17b-HSD10-binding interface) are in equilibrium between random coil and a-helical conformations. Over pH 4-7, this equilibrium includes a further b-sheet conformation. Taken together, our data suggest that such pH-induced conformational re-arrangement of the N terminus might be crucial to modulating the interaction of 17b-HSD10 with particular amyloid morphologies.
We extended our analysis of the interaction between Ab(1-42) and 17b-HSD10 by exploring how different aggregation conditions affect enzymatic activity. Although 17b-HSD10 efficiently inhibited the formation of fibrils and globules, rich amyloid conditions that promote the formation of fibrillar structures constitute a more toxic environment, and resulted in a 20.2 % decrease in enzymatic function (Figure 6 C) . The crystal structure of 17b-HSD10 bound to Ab indicates the presence of a large solvent cavity involving the L D loop, with estimated dimensions of 70 . This dimension is relatively close to the diameter of amyloid fibrils (4-6 nm) but much smaller than the average diameter for globular structures (~22 nm) measured by TEM and DLS. [34, 42] Therefore, it is possible that the higher enzymatic inhibition under fibril-forming conditions arises from the ability of these structures to drift and fit into this cavity and block the active site, thus inactivating the enzyme.
Our data also provide evidence for uncoupling the determinants that influence the formation of Ab-17b-HSD10 complexes from those that mediate suppression of enzymatic activity by amyloid fibrils at much higher Ab concentrations. High amyloid Ab(1-42)/17b-HSD10 molar ratios were required for a significant impact on activity; this agrees well with previous studies where the concentration of Ab for half-maximal inhibition was in the micromolar range (1-3 mm), rather than the nanomolar range (~40 nm) required for efficient binding, and more likely representative of the intracellular environment. [18] The need for a rich amyloid environment to impair activity is also supported by in vivo studies with SH-SY5Y (human neuroblastoma) cells, which showed a decrease in the efficiency of 17b-HSD10-catalysed estradiol-to-oestrone conversion upon incubation with a high concentration of Ab. [50] It has been suggested that the N-terminal domain of Ab is involved in the initial association to 17b-HSD10, and in a rich amyloid environment the C-terminal portion it is free to interact and recruit additional Ab molecules, thereby resulting in a macromolecular complex that distorts the enzyme and alters its function. [18] From all the evidence, we hypothesise that intracellular amyloid toxicity arises not exclusively from the formation of Ab17b-HSD10 complexes but from the recruitment of amyloid molecules that might disrupt, for example, the tertiary structure of the enzyme, thereby modifying substrate specificity or localisation, and thus increasing cell vulnerability. 
Conclusion
Biophysical characterisation of the Ab-17b-HSD10 interaction is pivotal for a full understanding of the interaction between Ab accumulated inside nerve cells and intracellular proteins. Unfortunately, the exact details of the Ab-17b-HSD10 interaction have not been elucidated by X-ray crystallography and, as demonstrated here, ThT-based methods to monitor amyloid aggregation and its inhibition by 17b-HSD10 are not suitable under all experimental conditions. Consequently, the range of amyloid morphologies capable of interacting with 17b-HSD10 has remained elusive. In this study, we took advantage of the robustness of fluorescence self-quenching to monitor the inhibitory efficiency of 17b-HSD10 against a range of amyloid morphologies. Our results demonstrate preferential inhibition by 17b-HSD10 towards globular and fibril-like aggregation under neutral conditions. The lack of inhibition towards amorphous plaque-like aggregates generated under slightly acidic conditions was discussed in terms of the known influence of pH on the conformational equilibrium of the Ab peptide N-terminal fragment, which contains the putative 17b-HSD10-binding interface. From the morphologies that were found to interact with 17b-HSD10, inhibition of acetoacetyl-CoA reduction was only detected under fibril-forming conditions and when Ab(1-42) was at concentrations much higher than those required for efficient binding. This work provides insights into the dependence of the Ab-17b-HSD10 interaction on the morphology of amyloid aggregates and suggests that the determinants that mediate Ab(1-42) binding to 17b-HSD10 are different from those that suppress 17b-HSD10 activity.
Experimental Section
All aqueous solutions were prepared in deionised water (Merck Millipore); all chemicals were purchased from Sigma-Aldrich unless stated otherwise.
17 b-HSD10 purification: Cell pellets of Escherichia coli BL21-CodonPlus (Agilent Technologies) containing Histev-17b-HSD10 protein [65] were re-suspended for 30 min at 4 8C in lysis buffer (sodium phosphate (20 mm, pH 7.5) containing imidazole (30 mm), NaCl (500 mm) and glycerol (10 %, v/v)) supplemented with complete EDTA-free protease inhibitor tablets (Roche), lysozyme (1 mg mL À1 ), DNase (20 mg mL À1 ) and Triton X-100 (0.1 %, v/v). Cells were lysed by passage at 20 6842.7 kPa through a cell disruptor (Constant Systems Ltd, Daventry, UK), and the lysate was cleared by centrifugation in a Sorvall Evolution RC (rotor S5-34, 55-34 angle, 20 500 rpm, 30 min, 4 8C). Cleared lysate was filtered (0.44 mm membrane; Whatman) then applied to a Ni-NTA column (GE Healthcare) equilibrated with lysis buffer, and the protein was eluted in lysis buffer containing 300 mm imidazole. Tobacco etch virus (TEV) protease was added at a molar ratio of 1:10, to cleave the histidine tag, and the protein was dialysed into Tris·HCl (20 mm, pH 7.5) with imidazole (30 mm), NaCl (500 mm) and glycerol (10 %, v/v), supplemented with EDTA (1 mm) and DTT (1 mm) to aid solubility. Protein digestion and dialysis was carried out at 4 8C for 16 h.
Complete digestion was verified by SDS-PAGE, then 17b-HSD10 protein was passed through a second Ni-column, and the flowthrough was concentrated to~7 mL in a Vivaspin column (10 kDa MWCO, GE Healthcare) before final purification by gel filtration to remove imidazole (Hi-Load 16/60 Superdex 75 prep grade column, GE Healthcare; flow rate 1.5 mL min À1 ). The protein was eluted in gel filtration buffer (Tris·HCl (10 mm, pH 7.5) NaCl (150 mm), glycerol (10 %)) and concentrated in the same Vivaspin column to 10 mg mL
À1
. Aliquots (10 mL) were taken and flash frozen in liquid nitrogen for storage at À80 8C.
17 b-HSD10 Activity Assay: 17b-HSD10 was diluted (0.2 mg mL À1 ) in assay buffer (Tris·HCl (10 mm, pH 7.5), NaCl (150 mm), glycerol 10 % (v/v)) at 30 8C. Acetoacetyl-CoA (AcAcCoA) was prepared at 4.8 mm in assay buffer; NADH was prepared at 10 mm in assay buffer. Enzyme activity was measured in a Nunc 96-well plate with the following concentrations: AcAcCoA (120 mm), NADH (250 mm), 17b-HSD10 (8 mg mL À1 ). 17b-HSD10 was added to initiate the reaction, and the initial rate was recorded over 30 s in a FLUOstar plate reader (BMG Labtech; l = 340 nm, T = 30 8C, 0.5 s orbital measuring intervals). Enzyme activity was calculated from e = 6220 m À1 cm
(NADH absorption coefficient); the NADH rate of consumption is the same as the AcAcCoA rate of reduction. Assays were performed in triplicate; data are mean AE SEM.
HiLyte Fluor 555: Synthetic dye labelled Ab1-42 peptides incorporating HiLyte Fluor 555 were purchased from Anaspec (Fremont, CA) and used without further purification (see the Supporting Information).
Amyloid monomer preparation and fluorescence spectroscopy of Ab(1-42) aggregates: The methods for amyloid monomer preparation and fluorescence spectroscopy of Ab(1-42) aggregates can be found in the Supporting Information.
Aggregation protocols: Aggregation protocols were as previously reported [33, 34, 52] (details in the Supporting Information).
Dynamic light scattering: see the Supporting Information.
